Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 406
Filter
Add more filters

Publication year range
1.
Neurocrit Care ; 41(1): 228-243, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38356077

ABSTRACT

Acute bacterial meningitis (ABM) is associated with severe morbidity and mortality. The most prevalent pathogens in community-acquired ABM are Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Other pathogens may affect specific patient groups, such as newborns, older patients, or immunocompromised patients. It is well established that ABM is associated with elevated intracranial pressure (ICP). However, the role of ICP monitoring and management in the treatment of ABM has been poorly described.An electronic search was performed in four electronic databases: PubMed, Web of Science, Embase, and the Cochrane Library. The search strategy chosen for this review used the following terms: Intracranial Pressure AND (management OR monitoring) AND bacterial meningitis. The search yielded a total of 403 studies, of which 18 were selected for inclusion. Eighteen studies were finally included in this review. Only one study was a randomized controlled trial. All studies employed invasive ICP monitoring techniques, whereas some also relied on assessment of ICP-based on clinical and/or radiological observations. The most commonly used invasive tools were external ventricular drains, which were used both to monitor and treat elevated ICP. Results from the included studies revealed a clear association between elevated ICP and mortality, and possibly improved outcomes when invasive ICP monitoring and management were used. Finally, the review highlights the absence of clear standardized protocols for the monitoring and management of ICP in patients with ABM. This review provides an insight into the role of invasive ICP monitoring and ICP-based management in the treatment of ABM. Despite weak evidence certainty, the present literature points toward enhanced patient outcomes in ABM with the use of treatment strategies aiming to normalize ICP using continuous invasive monitoring and cerebrospinal fluid diversion techniques. Continued research is needed to define when and how to employ these strategies to best improve outcomes in ABM.


Subject(s)
Community-Acquired Infections , Intracranial Hypertension , Meningitis, Bacterial , Humans , Meningitis, Bacterial/therapy , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/physiopathology , Intracranial Hypertension/therapy , Intracranial Hypertension/physiopathology , Intracranial Hypertension/diagnosis , Community-Acquired Infections/therapy , Acute Disease , Intracranial Pressure/physiology
2.
Nervenarzt ; 95(10): 909-919, 2024 Oct.
Article in German | MEDLINE | ID: mdl-39080056

ABSTRACT

Inflammatory causes of stroke are frequent and often pose diagnostic and therapeutic challenges due to the scarcity of randomized trials and the absence of clear guideline recommendations for many scenarios. Following the publication of the recommendations of the European Stroke Organization on primary angiitis of the central nervous system (PACNS) last year, the German Neurological Society (DGN) has issued very clear guidelines this year on the diagnostics and treatment of PACNS and updated the recommendations for systemic vasculitides; however, stroke often occurs not only as a result of primary vascular inflammation but also as a complication of another organ infection. Approximately 5% of all patients with sepsis, ca. 20% of patients with bacterial meningitis and up to 40% of patients with bacterial endocarditis suffer from a stroke as a complication. This article summarizes the key characteristics of these inflammatory causes of stroke and particularly focuses on the current recommendations for diagnostic and therapeutic management.


Subject(s)
Stroke , Humans , Stroke/diagnosis , Stroke/etiology , Stroke/therapy , Diagnosis, Differential , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/therapy , Meningitis, Bacterial/complications , Sepsis/diagnosis , Sepsis/therapy , Sepsis/complications , Vasculitis, Central Nervous System/diagnosis , Vasculitis, Central Nervous System/therapy
3.
BMC Infect Dis ; 21(1): 268, 2021 Mar 17.
Article in English | MEDLINE | ID: mdl-33731039

ABSTRACT

BACKGROUND: Neonatal meningitis is a severe infectious disease of the central nervous system with high morbidity and mortality. Ureaplasma parvum is extremely rare in neonatal central nervous system infection. CASE PRESENTATION: We herein report a case of U. parvum meningitis in a full-term neonate who presented with fever and seizure complicated with subdural hematoma. After hematoma evacuation, the seizure disappeared, though the fever remained. Cerebrospinal fluid (CSF) analysis showed inflammation with CSF pleocytosis (1135-1319 leukocytes/µl, mainly lymphocytes), elevated CSF protein levels (1.36-2.259 g/l) and decreased CSF glucose (0.45-1.21 mmol/l). However, no bacterial or viral pathogens in either CSF or blood were detected by routine culture or serology. Additionally, PCR for enteroviruses and herpes simplex virus was negative. Furthermore, the CSF findings did not improve with empirical antibiotics, and the baby experienced repeated fever. Thus, we performed metagenomic next-generation sequencing (mNGS) to identify the etiology of the infection. U. parvum was identified by mNGS in CSF samples and confirmed by culture incubation on mycoplasma identification medium. The patient's condition improved after treatment with erythromycin for approximately 5 weeks. CONCLUSIONS: Considering the difficulty of etiological diagnosis in neonatal U. parvum meningitis, mNGS might offer a new strategy for diagnosing neurological infections.


Subject(s)
Hematoma, Subdural/diagnosis , Meningitis, Bacterial/diagnosis , Ureaplasma Infections/diagnosis , Ureaplasma/isolation & purification , Anti-Bacterial Agents/therapeutic use , Hematoma, Subdural/complications , Hematoma, Subdural/therapy , Humans , Infant, Newborn , Male , Meningitis, Bacterial/complications , Meningitis, Bacterial/therapy , Metagenomics , Treatment Outcome , Ureaplasma/genetics , Ureaplasma Infections/complications , Ureaplasma Infections/therapy
4.
Acta Neurol Taiwan ; 30(4): 141-150, 2021 Dec 15.
Article in English | MEDLINE | ID: mdl-34841499

ABSTRACT

BACKGROUND: To examine the clinical characteristics and therapeutic outcome of Escherichia (E.) coli adult bacterial meningitis (ABM). METHODS: The demographic data, clinical and laboratory features and therapeutic outcome of 25 E. coli ABM patients were examined retrospectively. The clinical features of the reported E. coli ABM cases were also included for analysis. RESULTS: The 25 E. coli ABM patients included 12 women and 13 men, aged 33-78 years (mean= 59.9). Of these 25 patients, 13 had a postneurosurgical state as the underlying condition. As to the underlying medical conditions, diabetes mellitus was the most common, found in 9 of the 25 cases. Of the clinical manifestation, severe neurologic manifestations including altered consciousness (19), hydrocephalus (10), seizure (7) acute/subacute cerebral infarct (5), brain abscess (2), subdural empyema (1) and spinal abscess (1) were found, and the other clinical features included fever (21), septic shock (8), bacteremia (6) and hyponatremia (3). With treatment, the mortality rate was more than 44.0% and the presence of septic shock was a significant prognostic factor. With literature review, 29 community-acquired and 12 postneurosurgical E. coli ABM cases were enrolled, and severe neurologic manifestation and high mortality rate were also found. CONCLUSIONS: This preliminary overview of E. coli ABM revealed the underlying conditions, severe neurologic manifestation and high mortality rate. Further large-scale, prospective study is needed for a better delineation of this specific infectious syndrome of adult E. coli meningitis.


Subject(s)
Meningitis, Bacterial , Meningitis, Escherichia coli , Adult , Escherichia coli , Female , Humans , Male , Meningitis, Bacterial/therapy , Meningitis, Escherichia coli/therapy , Retrospective Studies , Treatment Outcome
5.
Brain ; 142(11): 3325-3337, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31373605

ABSTRACT

Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the complement system in upregulating and maintaining the inflammatory response in bacterial meningitis. Genetic variation studies, complement level measurements in blood and CSF, and experimental work have together led to the identification of anaphylatoxin C5a as a promising treatment target in bacterial meningitis. In animals and patients with pneumococcal meningitis, the accumulation of neutrophils in the CSF was mainly driven by C5-derived chemotactic activity and correlated positively with disease severity and outcome. In murine pneumococcal meningitis, adjunctive treatment with C5 antibodies prevented brain damage and death. Several recently developed therapeutics target C5 conversion, C5a, or its receptor C5aR. Caution is warranted because treatment with C5 antibodies such as eculizumab also inhibits the formation of the membrane attack complex, which may result in decreased meningococcal killing and increased meningococcal disease susceptibility. The use of C5a or C5aR antagonists to specifically target the harmful anaphylatoxins-induced effects, therefore, are most promising and present opportunities for a phase 2 clinical trial.


Subject(s)
Complement System Proteins/physiology , Meningitis, Bacterial/therapy , Animals , Complement C5a/genetics , Complement C5a/immunology , Complement System Proteins/cerebrospinal fluid , Complement System Proteins/drug effects , Humans , Immunotherapy , Inflammation/etiology , Inflammation/pathology , Meningitis, Bacterial/immunology , Meningitis, Bacterial/pathology , Mice
6.
Ann Intern Med ; 170(8): 521-530, 2019 04 16.
Article in English | MEDLINE | ID: mdl-30884525

ABSTRACT

Background: Population exposure to Bacillus anthracis spores could cause mass casualties requiring complex medical care. Rapid identification of patients needing anthrax-specific therapies will improve patient outcomes and resource use. Objective: To develop a checklist that rapidly distinguishes most anthrax from nonanthrax illnesses on the basis of clinical presentation and identifies patients requiring diagnostic testing after a population exposure. Design: Comparison of published anthrax case reports from 1880 through 2013 that included patients seeking anthrax-related care at 2 epicenters of the 2001 U.S. anthrax attacks. Setting: Outpatient and inpatient. Patients: 408 case patients with inhalation, ingestion, and cutaneous anthrax and primary anthrax meningitis, and 657 control patients. Measurements: Diagnostic test characteristics, including positive and negative likelihood ratios (LRs) and patient triage assignation. Results: Checklist-directed triage without diagnostic testing correctly classified 95% (95% CI, 93% to 97%) of 353 adult anthrax case patients and 76% (CI, 73% to 79%) of 647 control patients (positive LR, 3.96 [CI, 3.45 to 4.55]; negative LR, 0.07 [CI, 0.04 to 0.11]; false-negative rate, 5%; false-positive rate, 24%). Diagnostic testing was needed for triage in up to 5% of case patients and 15% of control patients and improved overall test characteristics (positive LR, 8.90 [CI, 7.05 to 11.24]; negative LR, 0.06 [CI, 0.04 to 0.09]; false-negative rate, 5%; false-positive rate, 11%). Checklist sensitivity and specificity were minimally affected by inclusion of pediatric patients. Sensitivity increased to 97% (CI, 94% to 100%) and 98% (CI, 96% to 100%), respectively, when only inhalation anthrax cases or higher-quality case reports were investigated. Limitations: Data on case patients were limited to nonstandardized, published observational reports, many of which lacked complete data on symptoms and signs of interest. Reporting bias favoring more severe cases and lack of intercurrent outbreaks (such as influenza) in the control populations may have improved test characteristics. Conclusion: A brief checklist covering symptoms and signs can distinguish anthrax from other conditions with minimal need for diagnostic testing after known or suspected population exposure. Primary Funding Source: U.S. Department of Health and Human Services.


Subject(s)
Anthrax/diagnosis , Checklist , Mass Casualty Incidents , Triage/methods , Adult , Algorithms , Anthrax/therapy , Female , Humans , Male , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/therapy , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/therapy , Sensitivity and Specificity , Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/therapy , United States
7.
Neurocrit Care ; 32(2): 586-595, 2020 04.
Article in English | MEDLINE | ID: mdl-31342450

ABSTRACT

BACKGROUND: Knowing the individual child's risk is highly useful when deciding on treatment strategies, especially when deciding on invasive procedures. In this study, we aimed to develop a new predictive score for children with bacterial meningitis and compare this with existing predictive scores and individual risk factors. METHODS: We developed the Meningitis Swedish Survival Score (MeningiSSS) based on a previous systematic review of risk factors. From this, we selected risk factors identified in moderate-to-high-quality studies that could be assessed at admission to the hospital. Using data acquired from medical records of 101 children with bacterial meningitis, we tested the overall capabilities of the MeningiSSS compared with four existing predictive scores using a receiver operating characteristic curve (ROC) analysis to assert the area under the curve (AUC). Finally, we tested all predictive scores at their cut-off levels using a Chi-square test. As outcome, we used a small number of predefined outcomes; in-hospital mortality, 30-day mortality, occurrence of neurological disabilities at discharge defined as Pediatric Cerebral Performance Category Scale category two to five, any type of complications occurring during the hospital stay, use of intensive care, and use of invasive procedures to monitor or manage the intracerebral pressure. RESULTS: For identifying children later undergoing invasive procedures to monitor or manage the intracerebral pressure, the MeningiSSS excelled in the ROC-analysis (AUC = 0.90) and also was the only predictive score able to identify all cases at its cut-off level (25 vs 0%, p < 0.01). For intensive care, the MeningiSSS (AUC = 0.79) and the Simple Luanda Scale (AUC = 0.75) had the best results in the ROC-analysis, whereas others performed less well (AUC ≤ 0.65). Finally, while none of the scores' results were significantly associated with complications, an elevated score on the MeningiSSS (AUC = 0.70), Niklasson Scale (AUC = 0.72), and the Herson-Todd Scale (AUC = 0.79) was all associated with death. CONCLUSIONS: The MeningiSSS outperformed existing predictive scores at identifying children later having to undergo invasive procedures to monitor or manage the intracerebral pressure in children with bacterial meningitis. Our results need further external validation before use in clinical practice. Thus, the MeningiSSS could potentially be helpful when making difficult decisions concerning intracerebral pressure management.


Subject(s)
Hospital Mortality , Intracranial Hypertension/diagnosis , Intracranial Pressure , Meningitis, Bacterial/physiopathology , Monitoring, Physiologic , Age Factors , Area Under Curve , Body Temperature , Child, Preschool , Critical Care , Decision Support Systems, Clinical , Decompressive Craniectomy , Drainage , Female , Functional Status , Haemophilus Infections/complications , Haemophilus Infections/physiopathology , Haemophilus Infections/therapy , Humans , Intracranial Hypertension/etiology , Intracranial Hypertension/physiopathology , Intracranial Hypertension/therapy , Leukopenia/physiopathology , Male , Meningitis, Bacterial/complications , Meningitis, Bacterial/therapy , Meningitis, Meningococcal/complications , Meningitis, Meningococcal/physiopathology , Meningitis, Meningococcal/therapy , Meningitis, Pneumococcal/complications , Meningitis, Pneumococcal/physiopathology , Meningitis, Pneumococcal/therapy , Mortality , ROC Curve , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/physiopathology , Risk Factors , Seizures/etiology , Seizures/physiopathology , Shock/etiology , Shock/physiopathology , Ventriculostomy
8.
Br Med Bull ; 131(1): 57-70, 2019 09 19.
Article in English | MEDLINE | ID: mdl-31556944

ABSTRACT

BACKGROUND: Acute bacterial meningitis (ABM) in adults is associated with a mortality that may exceed 30%. Immunization programs have reduced the global burden; in the UK, declining incidence but persistently high mortality and morbidity mean that clinicians must remain vigilant. SOURCES OF DATA: A systematic electronic literature search of PubMed was performed to identify all ABM literature published within the past 5 years. AREAS OF AGREEMENT AND CONTROVERSY: Clinical features cannot reliably distinguish between ABM and other important infectious and non-infectious aetiologies. Prompt investigation and empirical treatment are imperative. Lumbar puncture (LP) and cerebrospinal fluid microscopy, biochemistry and culture remain the mainstay of diagnosis, but molecular techniques are increasingly useful. The 2016 UK joint specialist societies' guideline provides expert recommendations for the management of ABM, yet published data suggest clinical care delivered in the UK is frequently not adherent. Anxiety regarding risk of cerebral herniation following LP, unnecessary neuroimaging, underutilization of molecular diagnostics and suboptimal uptake of adjunctive corticosteroids compromise management. GROWING POINTS: There is increasing recognition that current antibiotic regimens and adjunctive therapies alone are insufficient to reduce the mortality and morbidity associated with ABM. AREAS TIMELY FOR DEVELOPING RESEARCH: Research should be focused on optimization of vaccines (e.g. pneumococcal conjugate vaccines with extended serotype coverage), targeting groups at risk for disease and reservoirs for transmission; improving adherence to management guidelines; development of new faster, more accurate diagnostic platforms (e.g. novel point-of-care molecular diagnostics); and development of new adjunctive therapies (aimed at the host-inflammatory response and bacterial virulence factors).


Subject(s)
Community-Acquired Infections/prevention & control , Meningitis, Bacterial/prevention & control , Adjuvants, Pharmaceutic/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Adult , Antibiotic Prophylaxis , Antibodies/therapeutic use , Bacteriological Techniques , Cerebrospinal Fluid/microbiology , Community-Acquired Infections/epidemiology , Community-Acquired Infections/therapy , Drug Therapy, Combination , Humans , Meningitis, Bacterial/epidemiology , Meningitis, Bacterial/therapy , Meningitis, Meningococcal/epidemiology , Meningitis, Meningococcal/prevention & control , Meningitis, Meningococcal/therapy , Neisseria meningitidis , Neuroimaging/methods , Pneumococcal Infections/epidemiology , Pneumococcal Infections/prevention & control , Pneumococcal Infections/therapy , Specimen Handling , Spinal Puncture , United Kingdom/epidemiology
10.
South Med J ; 112(4): 217-221, 2019 04.
Article in English | MEDLINE | ID: mdl-30943540

ABSTRACT

Mycobacterium fortuitum is a rare, opportunistic pathogen most frequently contracted through contact with a contaminated source. An immunocompetent 26-year-old female patient presented to our institution with an infected lumboperitoneal (LP) shunt presenting as continued nonhealing wounds. After multiple debridements, shunt revisions, and wound closure failures, infectious disease specialists were consulted. The wound cultures returned positive for M. fortuitum and the shunt was removed. Cerebrospinal fluid studies revealed significant pleocytosis with normal opening pressure, and the patient was diagnosed as having secondary meningitis. After shunt removal, the patient was treated with intravenous and oral antibiotics, resulting in infection resolution. Five months later, a new LP shunt was placed without infection recurrence. Although M. fortuitum was previously reported in neurosurgical patients with ventriculoperitoneal shunts, which are summarized here, to date this is the first case in the literature of M. fortuitum meningitis from an LP shunt. This case demonstrates the importance of clinicians considering uncommon and slow-growing pathogens, as well as consulting infectious disease specialists for patients with persistent, unexplained infections.


Subject(s)
Catheter-Related Infections/diagnosis , Cerebrospinal Fluid Shunts , Meningitis, Bacterial/diagnosis , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium fortuitum , Pseudotumor Cerebri/surgery , Adult , Amikacin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Catheter-Related Infections/therapy , Device Removal , Female , Humans , Imipenem/therapeutic use , Immunocompetence , Meningitis, Bacterial/therapy , Mycobacterium Infections, Nontuberculous/therapy
11.
Clin Infect Dis ; 66(3): 321-328, 2018 01 18.
Article in English | MEDLINE | ID: mdl-29020334

ABSTRACT

Background: Early treatment is pivotal for favorable outcome in acute bacterial meningitis (ABM). Lumbar puncture (LP) is the diagnostic key. The aim was to evaluate the effect on outcome of adherence to European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), and Swedish guidelines regarding neuroimaging before LP. Methods: The cohort comprised 815 adult ABM patients in Sweden registered prospectively between 2008 and 2015. Primary endpoint was in-hospital mortality and secondary endpoint was favorable outcome at 2-6 months of follow-up. Results: Indications for neuroimaging before LP existed in 7%, 32%, and 65% according to Swedish, ESCMID, and IDSA guidelines, respectively. The adjusted odds ratio (aOR) was 0.48 (95% confidence interval [CI], .26-.89) for mortality and 1.52 (95% CI, 1.08-2.12) for favorable outcome if Swedish guidelines were followed. ESCMID guideline adherence resulted in aOR of 0.68 (95% CI, .38-1.23) for mortality and 1.05 (95% CI, .75-1.47) for favorable outcome. Following IDSA recommendations resulted in aOR of 1.09 (95% CI, .61-1.95) for mortality and 0.59 (95% CI, .42-.82) for favorable outcome. Performing prompt vs neuroimaging-preceded LP was associated with aOR of 0.38 (95% CI, .18-.77) for mortality and 2.11 (95% CI, 1.47-3.00) for favorable outcome. The beneficial effect of prompt LP was observed regardless of mental status and immunosuppression. Conclusions: Adherence to Swedish guidelines in ABM is associated with decreased mortality and increased favorable outcome in contrast to adherence to ESCMID or IDSA recommendations. Our findings support that impaired mental status and immunocompromised state should not be considered indications for neuroimaging before LP in patients with suspected ABM.


Subject(s)
Meningitis, Bacterial/diagnostic imaging , Practice Guidelines as Topic , Spinal Puncture , Time Factors , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Female , Guideline Adherence , Humans , Immunocompromised Host , Male , Meningitis, Bacterial/mortality , Meningitis, Bacterial/therapy , Middle Aged , Neuroimaging , Odds Ratio , Prospective Studies , Retrospective Studies , Sweden , Tomography, X-Ray Computed , Young Adult
12.
Cochrane Database Syst Rev ; 2: CD008806, 2018 02 06.
Article in English | MEDLINE | ID: mdl-29405037

ABSTRACT

BACKGROUND: Every day children and adults die from acute community-acquired bacterial meningitis, particularly in low-income countries, and survivors risk deafness, epilepsy and neurological disabilities. Osmotic therapies may attract extra-vascular fluid and reduce cerebral oedema, and thus reduce death and improve neurological outcomes.This is an update of a Cochrane Review first published in 2013. OBJECTIVES: To evaluate the effects of osmotic therapies added to antibiotics for acute bacterial meningitis in children and adults on mortality, deafness and neurological disability. SEARCH METHODS: We searched CENTRAL (2017, Issue 1), MEDLINE (1950 to 17 February 2017), Embase (1974 to 17 February 2017), CINAHL (1981 to 17 February 2017), LILACS (1982 to 17 February 2017) and registers of ongoing clinical trials (ClinicalTrials.com, WHO ICTRP) (21 February 2017). We also searched conference abstracts and contacted researchers in the field (up to 12 December 2015). SELECTION CRITERIA: Randomised controlled trials testing any osmotic therapy in adults or children with acute bacterial meningitis. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the search results and selected trials for inclusion. Results are presented using risk ratios (RR) and 95% confidence intervals (CI) and grouped according to whether the participants received steroids or not. We used the GRADE approach to assess the certainty of the evidence. MAIN RESULTS: We included five trials with 1451 participants. Four trials evaluated glycerol against placebo, and one evaluated glycerol against 50% dextrose; in addition three trials evaluated dexamethasone and one trial evaluated acetaminophen (paracetamol) in a factorial design. Stratified analysis shows no effect modification with steroids; we present aggregate effect estimates.Compared to placebo, glycerol probably has little or no effect on death in people with bacterial meningitis (RR 1.08, 95% CI 0.90 to 1.30; 5 studies, 1272 participants; moderate-certainty evidence), but may reduce neurological disability (RR 0.73, 95% CI 0.53 to 1.00; 5 studies, 1270 participants; low-certainty evidence).Glycerol may have little or no effect on seizures during treatment for meningitis (RR 1.08, 95% CI 0.90 to 1.30; 4 studies, 1090 participants; low-certainty evidence).Glycerol may reduce the risk of subsequent deafness (RR 0.64, 95% CI 0.44 to 0.93; 5 studies, 922 participants; low to moderate-certainty evidence).Glycerol probably has little or no effect on gastrointestinal bleeding (RR 0.93, 95% CI 0.39 to 2.19; 3 studies, 607 participants; moderate-certainty evidence). The evidence on nausea, vomiting and diarrhoea is uncertain (RR 1.09, 95% CI 0.81 to 1.47; 2 studies, 851 participants; very low-certainty evidence). AUTHORS' CONCLUSIONS: Glycerol was the only osmotic therapy evaluated, and data from trials to date have not demonstrated an effect on death. Glycerol may reduce neurological deficiency and deafness.


Subject(s)
Diuretics, Osmotic/therapeutic use , Glycerol/therapeutic use , Meningitis, Bacterial/therapy , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Anti-Bacterial Agents/therapeutic use , Child , Combined Modality Therapy/methods , Community-Acquired Infections/complications , Community-Acquired Infections/metabolism , Community-Acquired Infections/mortality , Community-Acquired Infections/therapy , Deafness/epidemiology , Deafness/prevention & control , Dexamethasone/therapeutic use , Diuretics, Osmotic/adverse effects , Epilepsy/prevention & control , Gastrointestinal Hemorrhage/prevention & control , Glucose/therapeutic use , Glycerol/adverse effects , Humans , Intracranial Pressure/physiology , Meningitis, Bacterial/complications , Meningitis, Bacterial/metabolism , Meningitis, Bacterial/mortality , Nervous System Diseases/epidemiology , Nervous System Diseases/prevention & control , Osmosis/physiology , Osmotic Pressure/physiology , Randomized Controlled Trials as Topic
13.
Emerg Med J ; 35(6): 361-366, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29563150

ABSTRACT

OBJECTIVE: To determine the outcome of children aged 2-14 years with cerebrospinal fluid (CSF) pleocytosis and at very low risk for bacterial meningitis managed as outpatients without antibiotics. METHODS: Multicentre, prospective, observational study conducted at nine Spanish paediatric EDs. Patients were diagnosed with meningitis based on clinical suspicion of meningitis and CSF pleocytosis when evaluated in the ED. Children between 2 and 14 years of age with pleocytosis and very low-risk criteria for bacterial meningitis (well appearing, Bacterial Meningitis Score (BMS)=0, procalcitonin (PCT)<0.5 ng/mL and observation without deterioration for less than 24 hours in the ED) were treated as outpatients without antibiotics pending CSF cultures. The primary composite outcome was a final diagnosis of bacterial meningitis or return to the ED for clinical deterioration. RESULTS: Of 182 children between 2 and 14 years old diagnosed with meningitis, 56 met the very low-risk criteria and 45 were managed as outpatients. None was diagnosed with bacterial meningitis or returned due to clinical deterioration. Another 31 patients with BMS=1 (due to a peripheral absolute neutrophil count (ANC)>10 000/mm3) and PCT <0.5 ng/mL were managed as outpatients, diagnosed with aseptic meningitis and did well. BMS using PCT had the same sensitivity but greater specificity than classic BMS. CONCLUSIONS: This set of low-risk criteria appears safe for the outpatient management without antibiotics of children with CSF pleocytosis. Larger studies are needed to evaluate the predictive values of replacing peripheral ANC with PCT in the BMS.


Subject(s)
Disease Management , Meningitis, Bacterial/therapy , Microbial Sensitivity Tests/statistics & numerical data , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Leukocyte Count/classification , Leukocyte Count/methods , Male , Meningitis, Bacterial/classification , Microbial Sensitivity Tests/methods , Monitoring, Ambulatory/methods , Prospective Studies , Severity of Illness Index , Spain
14.
P R Health Sci J ; 36(1): 41-43, 2017 03.
Article in English | MEDLINE | ID: mdl-28266699

ABSTRACT

We herein describe the case of a 65-year-old male patient who presented with Osler's triad, which is the combination of endocarditis, pneumonia, and meningitis. This report is even more unusual since the pathogen isolated was the invasive and virulent strain of Streptococcus pneumoniae serotype 3. The clinical entity described is also called Austrian syndrome. Even though rare in this antibiotic era, the syndrome remains one of high morbidity and mortality. This particular case is of paramount importance for the clinician reader. First, it documents the clinical features associated with invasive pneumococcal disease and the Austrian syndrome. Second, and equally important, it highlights why following the Surviving Sepsis Campaign guidelines saves lives. For this case, the following steps were taken: 1. As a surrogate for perfusion, early and aggressive fluid resuscitation therapy (guided by lactic acid levels) was instituted; 2. also early in the treatment, broad spectrum antibiotics were administered; 3. to guide antibiotic therapy, microbiological cultures were obtained. The patient subsequently improved and was transferred to the internal medicine ward to complete 4 weeks of antibiotic therapy.


Subject(s)
Endocarditis, Bacterial/diagnosis , Meningitis, Bacterial/diagnosis , Pneumonia, Pneumococcal/diagnosis , Aged , Anti-Bacterial Agents/administration & dosage , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/therapy , Fluid Therapy/methods , Humans , Male , Meningitis, Bacterial/microbiology , Meningitis, Bacterial/therapy , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/therapy , Streptococcus pneumoniae/isolation & purification , Syndrome , Treatment Outcome
15.
Rev Med Suisse ; 13(544-545): 66-69, 2017 Jan 11.
Article in French | MEDLINE | ID: mdl-28703540

ABSTRACT

Several outbreaks have made the news in 2016 : Ebola has come at an end, Zika is booming and a resurgence of yellow fever takes place in Africa. In Switzerland, two hospital outbreaks have been reported, caused by Mycobacterium chimerae and Burkholderia cepacia. A major new article has consolidated the notion that prolonged antibiotic therapy is unnecessary in Lyme disease. As multiresistant bacteria are increasing in frequency, innovative therapeutic approaches are under development. For lung infections, sensitive and specific methods are in need to refine their etiological diagnosis. In pneumonia, therapy can be shortened without risk compared with usual practice. Finally, the epidemiology of bacterial meningitis has changed in the last 10 years, with a decrease of incidence.


Plusieurs épidémies ont fait l'actualité en 2016 : celle d'Ebola qui est arrivée à son terme, celle de Zika qui est en pleine expansion et une résurgence de la fièvre jaune sur le continent africain. En Suisse, deux épidémies hospitalières ont été rapportées, dues aux bactéries Mycobacterium chimerae et Burkholderia cepacia. Un nouvel article majeur a consolidé la notion que l'antibiothérapie prolongée est inutile dans la maladie de Lyme. Les bactéries multirésistantes augmentent en fréquence ; des approches thérapeutiques innovatrices sont en développement. Pour les infections pulmonaires, on est toujours à la recherche de méthodes sensibles et spécifiques pour affiner le diagnostic étiologique. Dans la pneumonie, la durée du traitement peut être raccourcie sans risque par rapport à ce qui se fait usuellement. Enfin, l'épidémiologie des méningites bactériennes a beaucoup changé ces 10 dernières années, avec une diminution de l'incidence de cette maladie.


Subject(s)
Communicable Diseases , Anti-Bacterial Agents/classification , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/therapeutic use , Communicable Diseases/diagnosis , Communicable Diseases/epidemiology , Communicable Diseases/therapy , Communicable Diseases, Emerging/microbiology , Communicable Diseases, Emerging/therapy , Communicable Diseases, Emerging/virology , Drug Resistance, Multiple, Bacterial , Epidemics/statistics & numerical data , Humans , Lyme Disease/therapy , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/epidemiology , Meningitis, Bacterial/therapy , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/epidemiology , Virus Diseases/diagnosis , Virus Diseases/epidemiology , Virus Diseases/therapy
16.
Article in Russian | MEDLINE | ID: mdl-29393287

ABSTRACT

AIM: to determine the incidence rate and risk factors for drainage-associated meningitis in neurocritical care patients. MATERIAL AND METHODS: The prospective study included 539 patients who spent more than 48 h at the Department of Neurocritical Care and underwent external ventricular drainage. The incidence rate and risk factors for drainage-associated meningitis were evaluated. RESULTS: Over a 5-year period, 2140 patients have been hospitalized to the Department of Critical and Intensive Care (DCIC) for more than 48 h; of these, 539 patients underwent external ventricular drainage (EVD). Drainage-associated meningitis developed in 99 patients, which amounted to 19.8 (CI 16.3-23.3) per 100 patients with drainage and 18.3 (CI 14.3-22.2) per 1000 days of drainage. The incidence rate of drainage-associated meningitis did not significantly correlate with different neurosurgical diseases, but there was a tendency for meningitis to predominate in EVD patients with vascular pathology of the central nervous system (CNS). The rate of artery catheterization for direct measurement of systemic BP and the use of vasopressor agents were significantly higher in the group of patients with drainage-associated meningitis (p<0.05). ALV was used in 98 (99%) of 99 patients with drainage-associated meningitis; respiratory support was used in 325 (80.8%) patients without meningitis (p<0.01). An analysis of the ventricular drainage duration revealed a significantly (p<0.05) larger number of days of using EVD in the group of patients with drainage-associated meningitis. In most critical care patients (57.6%), meningitis developed during the first week of drainage. Cerebrospinal fluid leakage occurred significantly more frequently in patients with drainage-associated meningitis than in patients with EVD and without meningitis (p<0.01). Based on a microbiological examination, the etiology of drainage-associated meningitis was established in 57.1% of cases. The leading pathogens were coagulase-negative staphylococci (48.3%) and Acinetobacter baumannii (18.3%). CONCLUSION: The incidence rate of drainage-associated meningitis was 19.8 per 100 patients and 18.3 per 1000 days of drainage. The risk factors significantly predominating in patients with drainage-associated meningitis include the duration of drainage, association with external CSF leakage, as well as factors associated with indicators of the overall severity of the condition.


Subject(s)
Critical Care , Meningitis, Bacterial , Neurosurgical Procedures/adverse effects , Postoperative Complications , Cerebrospinal Fluid Leak/epidemiology , Cerebrospinal Fluid Leak/etiology , Cerebrospinal Fluid Leak/therapy , Female , Humans , Male , Meningitis, Bacterial/epidemiology , Meningitis, Bacterial/etiology , Meningitis, Bacterial/therapy , Postoperative Complications/epidemiology , Postoperative Complications/therapy , Prospective Studies
17.
Cochrane Database Syst Rev ; 11: CD004786, 2016 11 04.
Article in English | MEDLINE | ID: mdl-27813057

ABSTRACT

BACKGROUND: Acute bacterial meningitis remains a disease with high mortality and morbidity rates. However, with prompt and adequate antimicrobial and supportive treatment, the chances for survival have improved, especially among infants and children. Careful management of fluid and electrolyte balance is an important supportive therapy. Both over- and under-hydration are associated with adverse outcomes. This is the latest update of a review first published in 2005 and updated in 2008 and 2014. OBJECTIVES: To evaluate treatment of acute bacterial meningitis with differing volumes of initial fluid administration (up to 72 hours after first presentation) and the effects on death and neurological sequelae. SEARCH METHODS: For this 2016 update we searched the following databases up to March 2016: the Cochrane Acute Respiratory Infections Group's Specialised Register, CENTRAL, MEDLINE, CINAHL, Global Health, and Web of Science. SELECTION CRITERIA: Randomised controlled trials (RCTs) of differing volumes of fluid given in the initial management of bacterial meningitis were eligible for inclusion. DATA COLLECTION AND ANALYSIS: All four of the original review authors extracted data and assessed trials for quality in the first publication of this review (one author, ROW, has passed away since the original review; see Acknowledgements). The current authors combined data for meta-analysis using risk ratios (RRs) for dichotomous data or mean difference (MD) for continuous data. We used a fixed-effect statistical model. We assessed the overall quality of evidence using the GRADE approach. MAIN RESULTS: We included three trials with a total of 420 children; there were no trials in adult populations. The largest of the three trials was conducted in settings with high mortality rates and was judged to have low risk of bias for all domains, except performance bias which was high risk. The other two smaller trials were not of high quality.The meta-analysis found no significant difference between the maintenance-fluid and restricted-fluid groups in number of deaths (RR 0.82, 95% confidence interval (CI) 0.53 to 1.27; 407 participants; low quality of evidence) or acute severe neurological sequelae (RR 0.67, 95% CI 0.41 to 1.08; 407 participants; low quality of evidence). However, when neurological sequelae were defined further, there was a statistically significant difference in favour of the maintenance-fluid group for spasticity (RR 0.50, 95% CI 0.27 to 0.93; 357 participants); and seizures at both 72 hours (RR 0.59, 95% CI 0.42 to 0.83; 357 participants) and 14 days (RR 0.19, 95% CI 0.04 to 0.88; 357 participants). There was very low quality of evidence favouring maintenance fluid over restrictive fluid for chronic severe neurological sequelae at three months follow-up (RR 0.42, 95% CI 0.20 to 0.89; 351 participants). AUTHORS' CONCLUSIONS: The quality of evidence regarding fluid therapy in children with acute bacterial meningitis is low to very low and more RCTs need to be conducted. There is insufficient evidence to guide practice as to whether maintenance fluids should be chosen over restricted fluids in the treatment of acute bacterial meningitis.


Subject(s)
Fluid Therapy/standards , Meningitis, Bacterial/therapy , Acute Disease , Child , Developing Countries , Fluid Therapy/adverse effects , Fluid Therapy/methods , Humans , Hyponatremia/etiology , Infant , Meningitis, Bacterial/complications , Randomized Controlled Trials as Topic
18.
Acta Paediatr ; 105(1): e22-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26426265

ABSTRACT

AIM: This retrospective chart review aimed to identify factors in childhood bacterial meningitis that predicted disease severity and long-term outcome. METHODS: The study included 112 episodes of microbiologically confirmed bacterial meningitis in children aged three days to 15 years who were admitted to a Singapore hospital from 1998 to 2013. RESULTS: The mortality rate was 6%, and 44% required intensive care unit (ICU) admission. Predictive factors associated with ICU admission included pneumococcal meningitis, with an odds ratio (OR) of 5.2 and 95% confidence interval (CI) of 1.5-18.2, leukopenia (OR 5.6, 95% CI 1.7-17.9) and a cerebrospinal fluid (CSF):serum glucose ratio <0.25 (OR 4.5, 95% CI 1.4-14.4). An initial CSF white blood cell count >1000/mm(3) (OR 0.26, 95% CI 0.086-0.76) was negatively associated with ICU admission. Five years after meningitis, 32% had residual sequelae, and the associated prognostic factors were Haemophilus influenzae type b (Hib) meningitis (OR 29.5, 95% CI 2-429), seizures during their inpatient stay (OR 10.6, 95% CI 1.9-60.2) and septic shock (OR 8.4, 95% CI 1.1-62.1). CONCLUSION: As mortality was low in this bacterial meningitis study, ICU admission was used as a marker of disease severity. These findings underscore the importance of the pneumococcal and Hib meningitis vaccines.


Subject(s)
Gram-Negative Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/diagnosis , Meningitis, Bacterial/diagnosis , Adolescent , Child , Child, Preschool , Critical Care/statistics & numerical data , Female , Follow-Up Studies , Gram-Negative Bacterial Infections/complications , Gram-Negative Bacterial Infections/mortality , Gram-Negative Bacterial Infections/therapy , Gram-Positive Bacterial Infections/complications , Gram-Positive Bacterial Infections/mortality , Gram-Positive Bacterial Infections/therapy , Humans , Infant , Infant, Newborn , Logistic Models , Male , Meningitis, Bacterial/complications , Meningitis, Bacterial/mortality , Meningitis, Bacterial/therapy , Outcome Assessment, Health Care , Prognosis , Retrospective Studies , Severity of Illness Index , Singapore/epidemiology
19.
Internist (Berl) ; 57(2): 188-93, 2016 Feb.
Article in German | MEDLINE | ID: mdl-26780192

ABSTRACT

Benign recurrent aseptic meningitis (BRAM) or Mollaret's meningitis is a rare disease characterized by recurrent episodes of aseptic meningitis followed by spontaneous recovery. Disease courses over several years have been reported. In most cases, BRAM is caused by HSV-2, less frequently by other viruses or autoimmune diseases. In up to 10 %, the aetiology remains unclear. We present a case of idiopathic BRAM and discuss clinical findings, diagnosis and therapeutic options of this rare illness.


Subject(s)
Meningitis, Aseptic/diagnosis , Meningitis, Aseptic/therapy , Meningitis, Bacterial/diagnosis , Meningitis, Viral/diagnosis , Meningitis, Viral/therapy , Diagnosis, Differential , Female , Humans , Meningitis, Bacterial/therapy , Middle Aged , Recurrence , Symptom Assessment/methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL